Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pharmalink AB Strengthens Senior Management Team

Published: Thursday, February 21, 2013
Last Updated: Wednesday, February 20, 2013
Bookmark and Share
Dr. Heather Cook appointed director of regulatory affairs and Marek Poszepczynski as director of business development.

Pharmalink AB has announced that it has appointed Dr. Heather Cook as Director of Regulatory Affairs and Mr. Marek Poszepczynski as Director of Business Development.

Dr. Cook brings to Pharmalink over 15 years of experience within the pharmaceutical industry, with a proven track record in global regulatory affairs and clinical development.

Prior to joining Pharmalink, Dr. Cook was Head of Department for Regulatory Development Projects at H. Lundbeck A/S.

She was also Global Regulatory Affairs Director, Oncology for Astra Zeneca and held a number of other senior roles including Scientific Director for Neuroscience and Infection.

She has worked in the UK, Canada, and Denmark and currently resides in Stockholm. Dr. Cook is also Partner, Pharma and Biotech R&D consultant at PharmaView Consulting HB.

She has a PhD in Zoology from the University of Toronto and is completing an MBA at Stockholm School of Economics.

Marek Poszepczynski joins Pharmalink after a career spanning 10 years and combining financial and business development experience.

Before joining Pharmalink, Mr. Poszepczynski was lead equity analyst at Handelsbanken covering European and Swedish biotechnology stocks.

Prior to Handelsbanken, Mr. Poszepczynski was Vice President of Business Development at Karolinska Development, where he carried out a wide variety of tasks including streamlining the company’s business operations as well as taking part in M&A, licensing and fund raising negotiations.

Mr. Poszepczynski spent six years at BioVitrum AB where he was Director of Corporate Development, and part of the in-and-out licensing deals team of the company’s R&D portfolio.

Mr. Poszepczynski holds a Master of Industrial Engineering and Business Management from KTH Royal Institute of Technology, Stockholm.

Pharmalink’s Managing Director Johan Häggblad said, “These appointments add significant talent and new experience to Pharmalink’s management team as the Company continues to drive forward its late stage clinical development programs for Nefecon® and Busulipo™ and actively seeks new product opportunities. It is a measure of our reputation that such high caliber executives have joined us and I look forward to working with Heather and Marek through what is an exciting stage of development.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pharmalink Initiates Phase IIb Trial with Nefecon®
Pharmalink expects to announce top line results in the first half of 2015.
Friday, December 21, 2012
Pharmalink Enters Manufacturing Agreement for Nefecon®
Company has entered into a contract with Patheon.
Thursday, November 01, 2012
Pharmalink AB Raises SEK 35 Million through Share Issue
New funds used to further advance Nefecon® and Busulipo™.
Friday, January 06, 2012
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!